Tarsa Therapeutics announced completion of its global Phase 3 ORACAL trial evaluating a once-daily, oral recombinant calcitonin for the treatment of postmenopausal osteoporosis in 565 patients. Results are expected to be available in early spring. Additionally, Tarsa has initiated a Phase 2 multicenter, randomized, double-blind, placebo-controlled study designed to enroll approximately 120 postmenopausal women with low bone mass at increased risk of fracture to evaluate the efficacy of oral calcitonin in the prevention of osteoporosis in postmenopausal women.

Calcitonin helps maintain bone mass by acting on osteoclasts to limit bone resorption. It is currently approved for the treatment of postmenopausal osteoporosis in intranasal and injectable formulations.

For more information call (267) 273-7940 or visit www.tarsatherapeutics.com.